Sam Chun Dang Pharm. Co. Ltd (000250) - Total Assets
Based on the latest financial reports, Sam Chun Dang Pharm. Co. Ltd (000250) holds total assets worth ₩529.96 Billion KRW (≈ $359.14 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Sam Chun Dang Pharm. Co. Ltd net assets for net asset value and shareholders' equity analysis.
Sam Chun Dang Pharm. Co. Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Sam Chun Dang Pharm. Co. Ltd's total assets have evolved over time, based on quarterly financial data.
Sam Chun Dang Pharm. Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Sam Chun Dang Pharm. Co. Ltd's total assets of ₩529.96 Billion consist of 46.7% current assets and 53.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩6.00 Billion | 19.2% |
| Accounts Receivable | ₩35.91 Billion | 6.9% |
| Inventory | ₩38.19 Billion | 7.4% |
| Property, Plant & Equipment | ₩103.60 Billion | 19.9% |
| Intangible Assets | ₩118.44 Billion | 22.8% |
| Goodwill | ₩3.75 Billion | 0.7% |
Asset Composition Trend (2012–2024)
This chart illustrates how Sam Chun Dang Pharm. Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sam Chun Dang Pharm. Co. Ltd (000250) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sam Chun Dang Pharm. Co. Ltd's current assets represent 46.7% of total assets in 2024, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 19.2% of total assets in 2024, up from 5.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 6.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 22.8% of total assets.
Sam Chun Dang Pharm. Co. Ltd Competitors by Total Assets
Key competitors of Sam Chun Dang Pharm. Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Theragen Etex Co.Ltd
KQ:066700
|
Korea | ₩245.25 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩87.88 Billion |
|
Huons Global Co. Ltd
KQ:084110
|
Korea | ₩1.47 Trillion |
|
Kolon Life Science Inc
KQ:102940
|
Korea | ₩642.14 Billion |
Sam Chun Dang Pharm. Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.48 | 4.10 | 7.04 |
| Quick Ratio | 2.48 | 3.41 | 5.97 |
| Cash Ratio | 0.00 | 0.09 | 0.00 |
| Working Capital | ₩132.07 Billion | ₩180.71 Billion | ₩142.87 Billion |
Sam Chun Dang Pharm. Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Sam Chun Dang Pharm. Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 18.34 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 27.4% |
| Total Assets | ₩519.77 Billion |
| Market Capitalization | $6.03 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sam Chun Dang Pharm. Co. Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sam Chun Dang Pharm. Co. Ltd's assets grew by 27.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sam Chun Dang Pharm. Co. Ltd (2012–2024)
The table below shows the annual total assets of Sam Chun Dang Pharm. Co. Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩519.77 Billion ≈ $352.24 Million |
+27.39% |
| 2023-12-31 | ₩408.02 Billion ≈ $276.51 Million |
+9.45% |
| 2022-12-31 | ₩372.79 Billion ≈ $252.64 Million |
+7.74% |
| 2021-12-31 | ₩346.00 Billion ≈ $234.48 Million |
+9.12% |
| 2020-12-31 | ₩317.08 Billion ≈ $214.88 Million |
+9.28% |
| 2019-12-31 | ₩290.15 Billion ≈ $196.63 Million |
+11.10% |
| 2018-12-31 | ₩261.16 Billion ≈ $176.98 Million |
+13.48% |
| 2017-12-31 | ₩230.14 Billion ≈ $155.96 Million |
+12.20% |
| 2016-12-31 | ₩205.11 Billion ≈ $139.00 Million |
+11.32% |
| 2015-12-31 | ₩184.26 Billion ≈ $124.87 Million |
+6.82% |
| 2014-12-31 | ₩172.49 Billion ≈ $116.89 Million |
+11.01% |
| 2013-12-31 | ₩155.38 Billion ≈ $105.30 Million |
+27.28% |
| 2012-12-31 | ₩122.08 Billion ≈ $82.73 Million |
-- |
About Sam Chun Dang Pharm. Co. Ltd
Sam Chun Dang Pharm. Co., Ltd manufactures, distributes, imports, and exports pharmaceuticals in South Korea. It provides ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company was founded in 1943 and is headquartered in Seoul, S… Read more